Nivolumab for relapsed SCCHN approved by European Commission

The European Commission (EC) has approved nivolumab as monotherapy for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy. Nivolumab is the first and only Immuno-Oncology (I-O)...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2pBFxUu
via IFTTT